sameAs
Improving the success of mailed letter intervention programs to influence prescribing behaviors: a reviewAHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findingsDosing frequency and medication adherence in chronic diseaseEconomic burden of urgency urinary incontinence in the United States: a systematic reviewEvidence for long-term use of intramuscular interferon beta-1a: an overview of relapse, disability, and MRI data from selected clinical trialsCost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillationSummary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic ArthritisBiologic agents in rheumatoid arthritis: an update for managed care professionalsTotal first-year costs of acute coronary syndrome in a managed care settingValue for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACSComprehensive coronary artery disease care in a safety-net hospital: results of Get With The Guidelines quality improvement initiativePharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery diseaseAdherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen reviewThe burden of illness of irritable bowel syndrome: current challenges and hope for the futureHealth plan utilization and costs of specialty drugs within 4 chronic conditionsIncretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes.Patient-centric care management.Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.Emerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis.Influence of coadministration of antithrombotic medicines, warfarin, and NSAIDs on heparin safety: data from a prospective observational study.Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.Discrepancies identified with the use of prescription claims and diagnostic billing data following a comprehensive medication review.Assessing resource use in oncology patients: a comparison of analyses based on claims data and medical chart review.Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data.Health care professionals' perceptions of the role of pharmacogenomic data.Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data.Regression methods in the empiric analysis of health care data.Effects of electronic prescribing on formulary compliance and generic drug utilization in the ambulatory care setting: a retrospective analysis of administrative claims data.Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.An algorithm for the identification of undiagnosed COPD cases using administrative claims data.Clinical update on alefacept: consideration for use in patients with psoriasis.Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion.Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs.Actuarial analysis of private payer administrative claims data for women with endometriosis.LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.Influencing patient adherence to treatment guidelines.Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
P1433
Q26829612-B027F641-1414-4D2D-A165-B8DD22482DFAQ26830149-B644DF22-5A44-4AE8-A3EB-DFBA68C6FD75Q26830504-BF926AB8-11F7-4C9B-B750-72532D1D35A6Q26864020-3DD98A2B-DB1D-4525-8120-57EA21A9D3F4Q26997395-6461B788-E9D9-4536-AE60-A28519A655CBQ27006821-88B0913E-822A-4EDC-BE10-F119071373D1Q27014677-CC1043A6-004E-419E-A2B6-1434C74ABC82Q27023565-33DBA785-2CAF-4382-8EFC-6B26154D4812Q28174853-1335F37C-2E63-4FC7-B515-1483A52AF573Q28174863-400293CA-8CCB-4E4E-84FB-66379515E439Q28210853-17BD8F5D-F588-45E8-A15A-E8DE47809E4BQ28210869-066B48D9-95A1-4652-997B-016C74F5C2C7Q28218652-7A76359E-FA93-42F3-8D9A-8FF064B71CF2Q28275968-7A835B13-2783-44DB-947D-83D960E7AADFQ28297020-7D957CA6-5A5C-4586-BF29-257B3C3A0617Q30351342-F9C757CB-B2FD-4DDF-B438-C90A10E3AF06Q30354201-EEF487BB-1A43-4E81-8D6C-D87A689082C9Q30446241-10B282C7-FB57-4877-BBFA-BA5F95791FF8Q30587064-40525736-ACDE-4E47-AAF5-FF2438FFE555Q30651891-F2C40FFA-3257-4DA6-8139-7353F9D87678Q30670499-BDFA5D0B-C07D-4795-8C10-62C9C6627ADCQ30740983-2EF55E79-9BC1-4D0B-AFEE-93F0FCC0620BQ30884053-69E59C3C-971E-41F3-AD40-DC460A3E1E7CQ30884056-C697B9B5-4562-4E63-B06C-F451C5748CAAQ30884065-96738DE2-8CAF-414E-83B9-95C1AA979F83Q30940349-6F3B6164-947B-483B-8525-DB066ABBF2D7Q30986261-8CFF5CB2-92BB-4C20-8597-B7D716EF12E2Q30991335-2187F9EA-16D3-435E-BF6B-9E6495E94876Q31019919-3E0283FE-3C50-4433-8244-4F12485E9FB6Q31037049-38D0A5EE-8025-45F2-8D92-B18D24887033Q31056182-F3328A33-B3E6-4121-BBDA-CFE8AB052EECQ31093925-4C9C014B-5300-4B61-9A0D-82B98F940BBAQ31108071-7E7D6F13-A3BA-4DA3-A395-A0D94CE9E411Q31153721-FD2C0A56-0737-4D4D-8642-7351A26735DCQ33160275-3939FB74-3D32-44A2-AAF0-E02241375AE1Q33276207-91DB1705-0045-4099-9057-E26ACDB1A7BAQ33281054-19BACDDB-AC90-4A71-99D6-F4B9D9DCFCD0Q33304361-10622259-31BF-4B8F-9FD3-805A4165D2F9Q33345873-DFC6867D-1DA2-4670-AEDB-E63B8636CB61Q33390797-EDE0B6F6-46DD-4B6F-9936-E3335DD2F2DE
P1433
description
czasopismo naukowe
@pl
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
مجلة
@ar
name
Journal of Managed Care Pharmacy
@ast
Journal of Managed Care Pharmacy
@de
Journal of Managed Care Pharmacy
@en
Journal of Managed Care Pharmacy
@es
Journal of Managed Care Pharmacy
@fr
Journal of Managed Care Pharmacy
@it
Journal of Managed Care Pharmacy
@nl
type
label
Journal of Managed Care Pharmacy
@ast
Journal of Managed Care Pharmacy
@de
Journal of Managed Care Pharmacy
@en
Journal of Managed Care Pharmacy
@es
Journal of Managed Care Pharmacy
@fr
Journal of Managed Care Pharmacy
@it
Journal of Managed Care Pharmacy
@nl
prefLabel
Journal of Managed Care Pharmacy
@ast
Journal of Managed Care Pharmacy
@de
Journal of Managed Care Pharmacy
@en
Journal of Managed Care Pharmacy
@es
Journal of Managed Care Pharmacy
@fr
Journal of Managed Care Pharmacy
@it
Journal of Managed Care Pharmacy
@nl
P3181
P1055
P1058
P1156
P1277
P1476
Journal of Managed Care Pharmacy
@en